First evidence of RNA interference mechanism induced in human Getting closer to a cure?

Cell Adhesion and Migration

Volumn 5, Issue 1, 2011, Pages 1-3

  Roth, Lise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial; Melanoma; Nanoparticles; RNAi; Systemic administration

Indexed keywords

CYCLODEXTRIN; MESSENGER RNA; NANOPARTICLE; SMALL INTERFERING RNA;

CLINICAL LABORATORY; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); HUMAN; MOLECULARLY TARGETED THERAPY; NOTE; PROTEIN EXPRESSION; RNA INTERFERENCE; SOLID TUMOR;

EID: 78650847411     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.5.1.13490     Document Type: Note

References (5)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11.
2. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systematically administered siRNA via targeted nanoparticles. Nature 2010; 464:1067-70.
3. Gonzalez H, Hwang SJ, Davis ME. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug Chem 1999; 10:1068-74.
4. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007; 104:15549-54. (Pubitemid 47502954)
5. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Co-administration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010; 328:1031-5.